Advances in Computer Science : an International Journal
Software-As-A-Service for improving Drug Research towards a standardized approach
Abstract
Software as a Service (SaaS) is one of the most interesting applications of a service-oriented architecture. SaaS spares users the cost of acquiring and maintaining hardware and software. The SaaS business model is very widely appreciated in the economy, because it brings not only financial benefits but also process-optimizing benefits. Drug research is a lengthy, complex and costly process that involves a number of disciplines, from medicine through economics to natural science. Until recently, the standard programs and infrastructure used for data analysis were almost exclusively commercial, proprietary, closed source and expensive. One of the major attractions of the open-source model is to customize the platform to suite the requirements and react faster on changes. There are different proprietary approaches. However there is a gap in knowledge regarding using closed and proprietary infrastructure. The aim of this research is to investigate the impact of an open source SaaS approach on the drug research process.
Keywords
Full Text:
PDFReferences
K. Husein, SaaS als Alternative zu traditionellen IS in Unternehmen, Freie Universität Berlin, Germany: Diploma thesis, 2009.
Y. Tang, W. Zhu, K. Chen, H. Jiang, “New technologies in computer-aided drug design: Toward target identification and new chemical entity discovery”, Drug Discovery Today: Technologies vol. 3, no. 3, pp. 307-313, 2006.
W.L. Jorgensen, “The many roles of computation in drug discovery” Science, vol. 303, pp. 1813-1818, 2004.
G. Feuerlicht, “Next generation SOA: Can SOA survive cloud computing?” in Advances in Intelligent Web Mastering -2, AISC 67, pp. 19-29, 2010.
B. Coombe, “Cloud computing-overview, advantages, and challenges for enterprise deployment”, Bechtel Technology Journal, 2(1), pp. 1-11, 2009.
Cisco, “The Cisco powered network cloud: An exciting managed services opportunity.” Whitepaper, 2009.
D. Catteddu & G. Hogben, “Cloud computing: Benefits, risks and recommendations for information security”, European Network and Information Security Agency (ENISA), pp. 1-125, 2009.
T. Rapczynski, R. Siripanya, “Software as a Service für Unternehmensanwendungen”, Hft Stuttgart – University of Applied Science, Stuttgart – Germany, Research report, p. 2, 2008.
Medical Co. LTA Clinical Center, “How new drugs are developed”, www.rinsho.or.jp/en/01clinical_02.html, call on 16.12.2010.
AutoDock, “AutoDock history”, autodock.scripps.edu/resources/science/AutoDock/, call on 14.07.2013.
InhibOx, “InhibOx: Cloud-Enabled Drug Discovery”, http://www.inhibox.com/inhibox, called on 14.07.2013
F. Bost, R. T. Jacobs & P. Kowalczyk, “Informatics for neglected diseases collaborations”, Current Opinion in Drug Discovery & Development, vol. 13, no. 3, pp.286-296, 2010.
E-Science Central, “About: e-science central”, http://www.esciencecentral.co.uk/?page_id=10, called on 14.07.2013.
R. E. Amaro & W. W. Li, “Emerging Methods for Ensamble-Based Virtual Screening”, Current Topics in Medical Chemistry, Vol. 10, Issue 1, pp. 3-10, 2010.
Chemgapedia, “Liganden”, http://www.chemgapedia.de/ called on 22.03.2014
Baxter J. Local optima avoidance in depot location. Journal of the Operational Research Society. 1981; vol. 32(no. 9):815–819.
OpenStack,"What is OpenStack", http://www.openstack.org/, called on 22.03.2014
